Vesamicol and some of its derivatives: Questionable ligands for selectively labelling acetylcholine transporters in rat brain

被引:32
作者
Custers, FGJ
Leysen, JE
Stoof, JC
Herscheid, JDM
机构
[1] VRIJE UNIV AMSTERDAM,NEUROSCI RES INST,DEPT NEUROL,NL-1081 BT AMSTERDAM,NETHERLANDS
[2] JANSSEN RES FDN,DEPT BIOCHEM PHARMACOL,B-2340 BEERSE,BELGIUM
关键词
vesamicol; AH5183; Alzheimer's disease; acetylcholine transporter; sigma binding site; SPECT (single-photon emission computed tomography);
D O I
10.1016/S0014-2999(97)81946-2
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Presynaptic cholinergic markers could be used for estimating the integrity of the cholinergic systems in the human brain with brain imaging techniques such as Single-photon emission computed tomography (SPECT). Vesamicol, an inhibitor of the vesicular acetylcholine transporter, and some of its derivatives have been suggested as potential ligands for this purpose. However, vesamicol binds not only to acetylcholine transporters but also to sigma binding sites. In the present study, we estimated the contribution of sigma site labelling to [H-3](-)-vesamicol binding in different rat brain regions by selectively labelling the acetylcholine transporter, using [H-3](-)-vesamicol in the presence of the sigma-ligand 1,3-di(2-tolyl)guanidine to occlude the sigma binding sites. The contribution of sigma site labelling was substantial in all brain regions and ranged from 25% in the striatum to 60% in the medulla. In addition, we investigated, in various experimental set ups, the affinities of several vesamicol derivatives for acetylcholine transporters and sigma binding sites. All vesamicol derivatives used displayed a higher affinity for the sigma(1) site than for the acetylcholine transporter and also displayed a high sigma(2) site affinity. This poor selectivity limits the usefulness of these compounds as selective cholinergic markers for brain imaging studies. (C) 1997 Elsevier Science B.V.
引用
收藏
页码:177 / 183
页数:7
相关论文
共 15 条
[1]
[H-3] VESAMICOL BINDING IN BRAIN - AUTORADIOGRAPHIC DISTRIBUTION, PHARMACOLOGY, AND EFFECTS OF CHOLINERGIC LESIONS [J].
ALTAR, CA ;
MARIEN, MR .
SYNAPSE, 1988, 2 (05) :486-493
[2]
A DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF TACRINE FOR ALZHEIMERS-DISEASE [J].
DAVIS, KL ;
THAL, LJ ;
GAMZU, ER ;
DAVIS, CS ;
WOOLSON, RF ;
GRACON, SI ;
DRACHMAN, DA ;
SCHNEIDER, LS ;
WHITEHOUSE, PJ ;
HOOVER, TM ;
MORRIS, JC ;
KAWAS, CH ;
KNOPMAN, DS ;
EARL, NL ;
KUMAR, V ;
DOODY, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (18) :1253-1259
[3]
TACRINE [J].
DAVIS, KL ;
POWCHIK, P .
LANCET, 1995, 345 (8950) :625-630
[4]
DELOORE KL, 1994, NEUROSCI RES COMMUN, V14, P43
[5]
NONSYMMETRICAL BIPIPERIDYLS AS INHIBITORS OF VESICULAR ACETYLCHOLINE STORAGE [J].
EFANGE, SMN ;
KHARE, A ;
PARSONS, SM ;
BAU, R ;
METZENTHIN, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (08) :985-989
[6]
VESAMICOL ANALOGS AS SIGMA-LIGANDS - MOLECULAR DETERMINANTS OF SELECTIVITY AT THE VESAMICOL RECEPTOR [J].
EFANGE, SMN ;
MACH, RH ;
SMITH, CR ;
KHARE, AB ;
FOULON, C ;
AKELLA, SK ;
CHILDERS, SR ;
PARSONS, SM .
BIOCHEMICAL PHARMACOLOGY, 1995, 49 (06) :791-797
[7]
[H-3] VESAMICOL BINDING IN HUMAN BRAIN CHOLINERGIC DEFICIENCY DISORDERS [J].
KISH, SJ ;
DISTEFANO, LM ;
DOZIC, S ;
ROBITAILLE, Y ;
RAJPUT, A ;
DECK, JHN ;
HORNYKIEWICZ, O .
NEUROSCIENCE LETTERS, 1990, 117 (03) :347-352
[8]
IMMORTALIZED YOUNG-ADULT NEURONS FROM THE SEPTAL REGION - GENERATION AND CHARACTERIZATION [J].
LEE, HJ ;
HAMMOND, DN ;
LARGE, TH ;
WAINER, BH .
DEVELOPMENTAL BRAIN RESEARCH, 1990, 52 (1-2) :219-228
[9]
THE VESICULAR ACETYLCHOLINE TRANSPORT-SYSTEM [J].
MARSHALL, IG ;
PARSONS, SM .
TRENDS IN NEUROSCIENCES, 1987, 10 (04) :174-177
[10]
MOHS RC, 1985, AM J PSYCHIAT, V142, P28